Fatigue in cancer patients receiving chemotherapy: an analysis of published studies

In their review article, Iop et al. [1] carefully evaluated the usually overlooked problem of fatigue in cancer patients receiving chemotherapy, and they should be congratulated on their work. However, we would like to stress the point that cancer-related fatigue also occurs in patients after the time of therapy, and without any connection to the kind of chemotherapy they have received. Fatigue occurring during chemotherapy is predictable, unlike that which develops in patients who are not receiving chemotherapy, which can last years after chemotherapy. Usually this cancer-related fatigue is a non-specific, multidimensional construct characterized by debilitating lassitude unrestored by rest, decreased capacity in maintaining performance, generalized weakness defined as the anticipatory sensation of difficulty in starting a new activity, mental fatigue defined as the presence of impaired mental concentration, loss of memory and emotional lability. Sleep disorders are also frequently reported. Joly et al. [2] reported a statistically significant difference in chronic fatigue in long-term survivors of Hodgkin’s disease in comparison with healthy controls. The fatigue levels in these patients remain high even years after treatment. In addition, Andrykowski et al. [3] and Broeckel et al. [4] found higher levels of fatigue, more weakness and less vitality following treatment for breast cancer compared with an age-matched group of woman with no history of cancer. This fatigue syndrome seems to be similar to the one observed in patients (without cancer) who are affected by chronic fatigue syndrome according to the CDC definition [5]. However, the definition of chronic fatigue syndrome is based on exclusion criteria, and cancer is one of the diseases that must be excluded prior to this diagnosis. In conclusion, during a follow-up visit medical oncologists should be aware of the fact that cancer-related fatigue could have developed in their patients and should therefore take care that this syndrome is not ignored.

S. Spazzapan, A. Bearz & U. Tirelli*
Division of Medical Oncology A, National Cancer Institute, Aviano, Italy (*E-mail: oma@cro.it)

References


doi:10.1093/annonc/mdh400

Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-fluorouracil and infusional 5-fluorouracil alone in advanced pancreatic carcinoma patients

Advanced pancreatic carcinoma carries a poor prognosis, with a median survival \( \sim 3–6 \) months. In a randomized phase II study of patients with advanced pancreatic carcinoma, Ducreux and colleagues evaluated oxaliplatin 130 mg/m\(^2\) alone, oxaliplatin with 5-fluorouracil (5-FU) (1000 mg/m\(^2\) days 1–4) and 5-FU alone [1]. Combination chemotherapy gave the best results, with a response rate of 10\%, median time to progression of 4.2 months and median survival of 9 months. Nevertheless, this study is questionable in several aspects. The first point is the choice of the single-agent arms, which led to short survivals (2.4 and 3.4 months with 5-FU and oxaliplatin, respectively), confirming its inefficacy. The current study started in November 1997, despite the fact that after the publication of Burris et al. [2] in June 1997, gemcitabine rapidly became the standard care. Moreover, gemcitabine administered at fixed dose rate seems to be even more efficacious. Although combinations of 5-FU and cisplatin have frequently been used in patients with good general status in France, 5-FU alone has not been administered for many years. Despite an inevitable selection of relatively favourable cases, several recent studies have demonstrated that 5-FU alone gives no responses and does not prolong survival [2, 3].